Announcement regarding the meeting of the Tariff Council on 26 February 2026

At its meeting on 26 February 2026, the Council, having reviewed the presented material, issued a position on the tariffs for guaranteed hospital treatment services covering diagnostic lump sums under oncology drug programs.
The Council reviewed the results of the implementation cost analysis together with a proposal for a financing model for genetic testing services, including diagnostic services based on next-generation high-throughput sequencing (NGS) technologies, such as HRD testing in the diagnosis of malignant tumors, targeted NGS panels, multigene tests for early breast cancer, monogenic diabetes diagnostics, and tests for familial hypercholesterolemia in children under 18 years of age. The Council discussed the presented material.